Literature DB >> 26090509

Widespread arterial infection by varicella-zoster virus explains refractory giant cell arteritis.

Don Gilden1, Teresa White1, Steven L Galetta1, Franz Fogt1, Maria A Nagel1.   

Abstract

Entities:  

Year:  2015        PMID: 26090509      PMCID: PMC4459044          DOI: 10.1212/NXI.0000000000000125

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
Virologic analysis of tissues from a patient with giant cell arteritis (GCA) who was treated with corticosteroids and died of extensive necrotizing granulomatous arteritis revealed widespread varicella-zoster virus (VZV) antigen in multiple large arteries. Long-term treatment with corticosteroids likely potentiated VZV infection. In 1997, a clinicopathologic case report[1] described a 75-year-old woman with fatal aggressive steroid-refractory GCA that manifested as bilateral vision loss and myelopathy while on treatment with corticosteroids. The woman was not otherwise immunocompromised before becoming ill, and no cutaneous signs of herpesvirus infection developed during her 5-month illness. Bilateral temporal artery (TA) biopsies revealed GCA. Postmortem examination revealed spinal cord infarction secondary to extensive necrotizing granulomatous arteritis of spinal arteries. Based on detection of VZV in GCA-positive TAs[2] and documented involvement of other large arteries in most patients with GCA,[3] we revisited this case and searched for VZV in the archived TAs and in other large arteries, the spinal cord, and brain. Immunohistochemical examination detected VZV antigen (figure) in both TAs, in the aorta, in the left carotid artery, and in an unidentified artery from the Circle of Willis but not in renal or mesenteric arteries. Viral antigen was not seen in the brain or spinal cord. DNA extracted from every section of each VZV antigen–positive artery was analyzed by PCR with primers specific for VZV and herpes simplex virus (HSV)-1 as described[2] and revealed VZV DNA, but not HSV-1 DNA, in the unidentified cerebral artery from the Circle of Willis despite formalin fixation.
Figure

Varicella-zoster virus antigen in the temporal artery, aorta, and carotid artery of a patient with refractory giant cell arteritis

Immunohistochemical staining with mouse anti–varicella-zoster virus (VZV) gE IgG1 antibody[2] revealed VZV antigen in the media of the temporal artery (A), the media (B) and intima (C) of the aorta, and the intima of the carotid artery (D) that was not seen when mouse isotype control antibody was substituted for anti-VZV gE IgG1 antibody (E–H).

Varicella-zoster virus antigen in the temporal artery, aorta, and carotid artery of a patient with refractory giant cell arteritis

Immunohistochemical staining with mouse anti–varicella-zoster virus (VZV) gE IgG1 antibody[2] revealed VZV antigen in the media of the temporal artery (A), the media (B) and intima (C) of the aorta, and the intima of the carotid artery (D) that was not seen when mouse isotype control antibody was substituted for anti-VZV gE IgG1 antibody (E–H).

Discussion.

The pathologic diagnosis of VZV arteritis comes nearly 20 years after this patient's death. Reexamination of this case was prompted by the recognition that VZV is commonly found in the TAs of patients with GCA. VZV and extensive granulomatous arteritis in multiple large arteries was most likely due to reactivation of VZV in an elderly woman followed by potentiation of virus infection by several months of high-dose corticosteroids. Widespread vasculopathy occurs in patients with GCA treated with long-term corticosteroids.[4] Recently, virologic studies in a man with thoracic-distribution zoster and a history of corticosteroid abuse who died suddenly revealed extensive VZV infection in multiple organs and arteries, particularly the coronary arteries and aorta, along with subclinical VZV vasculopathy.[5] Large artery involvement in GCA has been increasingly documented.[3,6] Finally, our findings confirm detection of VZV antigen and VZV DNA in GCA-positive TAs[2,7] and indicate that productive VZV infection in the TAs of patients with GCA parallels productive VZV infection in intracerebral arteries of patients with VZV vasculopathy. In fact, GCA is likely to be a form of VZV vasculopathy that predominantly, but not exclusively, affects the TA. Because VZV is triggering the immunopathology of GCA, it is likely that treatment of GCA patients with antiviral agents will not only shorten the course of corticosteroids needed to reduce the immunopathology that produces disease but also prevent spread of VZV and the development of disseminated granulomatous arteritis.
  7 in total

1.  Varicella zoster virus in the temporal artery of a patient with giant cell arteritis.

Authors:  Maria A Nagel; Nelly Khmeleva; Philip J Boyer; Alexander Choe; Robert Bert; Don Gilden
Journal:  J Neurol Sci       Date:  2013-10-02       Impact factor: 3.181

2.  Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.

Authors:  Sergio Prieto-González; Pedro Arguis; Ana García-Martínez; Georgina Espígol-Frigolé; Itziar Tavera-Bahillo; Montserrat Butjosa; Marcelo Sánchez; José Hernández-Rodríguez; Josep M Grau; Maria C Cid
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

3.  Disseminated VZV infection and asymptomatic VZV vasculopathy after steroid abuse.

Authors:  Maria A Nagel; Daniela Lenggenhager; Teresa White; Nelly Khmeleva; Anna Heintzman; Philip J Boyer; Don Gilden
Journal:  J Clin Virol       Date:  2015-03-18       Impact factor: 3.168

4.  Refractory giant cell arteritis with spinal cord infarction.

Authors:  S L Galetta; L J Balcer; A P Lieberman; N A Syed; J M Lee; J C Oberholtzer
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

5.  Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis.

Authors:  Don Gilden; Teresa White; Nelly Khmeleva; Anna Heintzman; Alexander Choe; Philip J Boyer; Charles Grose; John E Carpenter; April Rempel; Nathan Bos; Balasubramaniyam Kandasamy; Kelly Lear-Kaul; Dawn B Holmes; Jeffrey L Bennett; Randall J Cohrs; Ravi Mahalingam; Naresh Mandava; Charles G Eberhart; Brian Bockelman; Robert J Poppiti; Madhura A Tamhankar; Franz Fogt; Malena Amato; Edward Wood; Vikram Durairaj; Steve Rasmussen; Vigdis Petursdottir; Lea Pollak; Sonia Mendlovic; Denis Chatelain; Kathy Keyvani; Wolfgang Brueck; Maria A Nagel
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

6.  Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.

Authors:  Dirk M Nuenninghoff; Gene G Hunder; Teresa J H Christianson; Robyn L McClelland; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2003-12

7.  Extensive intracranial involvement with multiple dissections in a case of giant cell arteritis.

Authors:  Joana Parra; Joana Domingues; João Sargento-Freitas; Isabel Santana
Journal:  BMJ Case Rep       Date:  2014-04-11
  7 in total
  5 in total

1.  Varicella Zoster Virus and Giant Cell Arteritis.

Authors:  Anne A Gershon; Michael Gershon
Journal:  J Infect Dis       Date:  2016-03-31       Impact factor: 5.226

Review 2.  Varicella zoster virus and giant cell arteritis.

Authors:  Don Gilden; Maria A Nagel
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

Review 3.  Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults.

Authors:  Catherine Amlie-Lefond; Don Gilden
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-04-29       Impact factor: 2.136

Review 4.  Varicella zoster virus triggers the immunopathology of giant cell arteritis.

Authors:  Don Gilden; Maria A Nagel
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

Review 5.  Developments in Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 6.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.